Production (Stage)
Cardiff Oncology, Inc.
CRDF
$3.86
$0.051.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -27.81% | -8.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -27.81% | -8.48% | |||
| Cost of Revenue | 7.88% | 0.75% | |||
| Gross Profit | -8.44% | -0.91% | |||
| SG&A Expenses | 33.31% | -3.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.90% | -0.34% | |||
| Operating Income | -14.40% | 0.23% | |||
| Income Before Tax | -13.97% | 0.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.97% | 0.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.97% | 0.57% | |||
| EBIT | -14.40% | 0.23% | |||
| EBITDA | -14.53% | 0.19% | |||
| EPS Basic | 7.13% | 14.07% | |||
| Normalized Basic EPS | 7.14% | 14.04% | |||
| EPS Diluted | 7.13% | 14.07% | |||
| Normalized Diluted EPS | 7.14% | 14.04% | |||
| Average Basic Shares Outstanding | 22.70% | 15.69% | |||
| Average Diluted Shares Outstanding | 22.70% | 15.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||